FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells

Dongyoung Kim, Hui Yun Hwang, Jin Young Kim, Ju Yeon Lee, Jong Shin Yoo, György Marko-Varga, Ho Jeong Kwon

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The drug FK506 (tacrolimus, fujimycin) exerts its immunosuppressive effects by regulating the nuclear factor of the activated T-cell (NFAT) family of transcription factors. However, FK506 also exhibits neuroprotective effects, but its direct target proteins that mediate these effects have not been determined. To identify the target proteins responsible for FK506's neuroprotective effects, the drug affinity responsive target stability (DARTS) method was performed using label-free FK506, and LC-MS/MS analysis of the FK506-treated proteome was also performed. Using DARTS and LC-MS/MS analyses in combination with reference studies, V-ATPase catalytic subunit A (ATP6V1A) was identified as a new target protein of FK506. The biological relevance of ATP6V1A in mediating the neuroprotective effects of FK506 was validated by analyzing FK506 activity with respect to autophagy via acridine orange staining and transcription factor EB (TFEB) translocation assay. These analyses demonstrated that the binding of FK506 with ATP6V1A induces autophagy by activating the translocation of TFEB from the cytosol into the nucleus. Because autophagy has been identified as a mechanism for treating neurodegenerative diseases and because we have demonstrated that FK506 induces autophagy, this study demonstrates that FK506 is a possible new therapy for treating neurodegenerative diseases.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalJournal of Proteome Research
Volume16
Issue number1
DOIs
Publication statusPublished - 2017 Jan 6

Fingerprint

Autophagy
Tacrolimus
Immunosuppressive Agents
Adenosine Triphosphatases
Catalytic Domain
Pharmaceutical Preparations
Neuroprotective Agents
Neurodegenerative diseases
Transcription Factors
Neurodegenerative Diseases
Activating Transcription Factors
NFATC Transcription Factors
Acridine Orange
Proteins
Proteome
Cytosol
Labels
Assays
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Chemistry(all)

Cite this

Kim, Dongyoung ; Hwang, Hui Yun ; Kim, Jin Young ; Lee, Ju Yeon ; Yoo, Jong Shin ; Marko-Varga, György ; Kwon, Ho Jeong. / FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells. In: Journal of Proteome Research. 2017 ; Vol. 16, No. 1. pp. 55-64.
@article{efce6ec179464f38acddf49e333a4a9a,
title = "FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells",
abstract = "The drug FK506 (tacrolimus, fujimycin) exerts its immunosuppressive effects by regulating the nuclear factor of the activated T-cell (NFAT) family of transcription factors. However, FK506 also exhibits neuroprotective effects, but its direct target proteins that mediate these effects have not been determined. To identify the target proteins responsible for FK506's neuroprotective effects, the drug affinity responsive target stability (DARTS) method was performed using label-free FK506, and LC-MS/MS analysis of the FK506-treated proteome was also performed. Using DARTS and LC-MS/MS analyses in combination with reference studies, V-ATPase catalytic subunit A (ATP6V1A) was identified as a new target protein of FK506. The biological relevance of ATP6V1A in mediating the neuroprotective effects of FK506 was validated by analyzing FK506 activity with respect to autophagy via acridine orange staining and transcription factor EB (TFEB) translocation assay. These analyses demonstrated that the binding of FK506 with ATP6V1A induces autophagy by activating the translocation of TFEB from the cytosol into the nucleus. Because autophagy has been identified as a mechanism for treating neurodegenerative diseases and because we have demonstrated that FK506 induces autophagy, this study demonstrates that FK506 is a possible new therapy for treating neurodegenerative diseases.",
author = "Dongyoung Kim and Hwang, {Hui Yun} and Kim, {Jin Young} and Lee, {Ju Yeon} and Yoo, {Jong Shin} and Gy{\"o}rgy Marko-Varga and Kwon, {Ho Jeong}",
year = "2017",
month = "1",
day = "6",
doi = "10.1021/acs.jproteome.6b00638",
language = "English",
volume = "16",
pages = "55--64",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "1",

}

FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells. / Kim, Dongyoung; Hwang, Hui Yun; Kim, Jin Young; Lee, Ju Yeon; Yoo, Jong Shin; Marko-Varga, György; Kwon, Ho Jeong.

In: Journal of Proteome Research, Vol. 16, No. 1, 06.01.2017, p. 55-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells

AU - Kim, Dongyoung

AU - Hwang, Hui Yun

AU - Kim, Jin Young

AU - Lee, Ju Yeon

AU - Yoo, Jong Shin

AU - Marko-Varga, György

AU - Kwon, Ho Jeong

PY - 2017/1/6

Y1 - 2017/1/6

N2 - The drug FK506 (tacrolimus, fujimycin) exerts its immunosuppressive effects by regulating the nuclear factor of the activated T-cell (NFAT) family of transcription factors. However, FK506 also exhibits neuroprotective effects, but its direct target proteins that mediate these effects have not been determined. To identify the target proteins responsible for FK506's neuroprotective effects, the drug affinity responsive target stability (DARTS) method was performed using label-free FK506, and LC-MS/MS analysis of the FK506-treated proteome was also performed. Using DARTS and LC-MS/MS analyses in combination with reference studies, V-ATPase catalytic subunit A (ATP6V1A) was identified as a new target protein of FK506. The biological relevance of ATP6V1A in mediating the neuroprotective effects of FK506 was validated by analyzing FK506 activity with respect to autophagy via acridine orange staining and transcription factor EB (TFEB) translocation assay. These analyses demonstrated that the binding of FK506 with ATP6V1A induces autophagy by activating the translocation of TFEB from the cytosol into the nucleus. Because autophagy has been identified as a mechanism for treating neurodegenerative diseases and because we have demonstrated that FK506 induces autophagy, this study demonstrates that FK506 is a possible new therapy for treating neurodegenerative diseases.

AB - The drug FK506 (tacrolimus, fujimycin) exerts its immunosuppressive effects by regulating the nuclear factor of the activated T-cell (NFAT) family of transcription factors. However, FK506 also exhibits neuroprotective effects, but its direct target proteins that mediate these effects have not been determined. To identify the target proteins responsible for FK506's neuroprotective effects, the drug affinity responsive target stability (DARTS) method was performed using label-free FK506, and LC-MS/MS analysis of the FK506-treated proteome was also performed. Using DARTS and LC-MS/MS analyses in combination with reference studies, V-ATPase catalytic subunit A (ATP6V1A) was identified as a new target protein of FK506. The biological relevance of ATP6V1A in mediating the neuroprotective effects of FK506 was validated by analyzing FK506 activity with respect to autophagy via acridine orange staining and transcription factor EB (TFEB) translocation assay. These analyses demonstrated that the binding of FK506 with ATP6V1A induces autophagy by activating the translocation of TFEB from the cytosol into the nucleus. Because autophagy has been identified as a mechanism for treating neurodegenerative diseases and because we have demonstrated that FK506 induces autophagy, this study demonstrates that FK506 is a possible new therapy for treating neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=85017592664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017592664&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.6b00638

DO - 10.1021/acs.jproteome.6b00638

M3 - Article

C2 - 28056508

AN - SCOPUS:85017592664

VL - 16

SP - 55

EP - 64

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 1

ER -